Ascendis Pharma ADR
(ASND)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 168,006 | 199,552 | 83,170 | 102,515 | 112,378 |
| Receivables | 3,379 | 1,845 | 3,984 | 2,414 | 2,823 |
| TOTAL | $177,378 | $203,568 | $89,916 | $109,060 | $117,553 |
| Non-Current Assets | |||||
| PPE Net | 2,727 | 2,601 | 2,703 | 2,745 | 2,572 |
| Intangibles | 3,725 | 3,868 | 3,900 | 3,948 | 3,856 |
| Other Non-Current Assets | 285 | 297 | 296 | 296 | 328 |
| TOTAL | $6,736 | $6,765 | $6,899 | $6,989 | $6,755 |
| Total Assets | $184,115 | $210,333 | $96,815 | $116,048 | $124,308 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 18,643 | 14,472 | 12,718 | 11,410 | 9,197 |
| TOTAL | $19,116 | $14,893 | $13,784 | $13,358 | $11,878 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 100 | 104 | 935 | 1,788 | 2,567 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $19,116 | $14,893 | $13,784 | $13,358 | $11,878 |
| Shareholders' Equity | |||||
| Common Shares | 4,652 | 4,818 | 3,778 | 3,820 | 3,722 |
| Retained earnings | 143,601 | 176,231 | 66,792 | 88,083 | 100,125 |
| Other shareholders' equity | 16,746 | 14,391 | 12,462 | 10,788 | 8,582 |
| TOTAL | $164,999 | $195,440 | $83,032 | $102,691 | $112,429 |
| Total Liabilities And Equity | $184,115 | $210,333 | $96,815 | $116,048 | $124,308 |